Prepared by Professor Alan Whiteside, OBE, Chair of Global Health Policy, BSIA, Waterloo, Canada & Professor Emeritus, University of KwaZulu-Natal – www.alan-whiteside.com
Spring is well entrenched in Norfolk. The leaves are appearing with great speed, the daffodils are past their best, and it is delightfully warm in the sunshine. Traditionally Spring is a time of regeneration and hopefulness. This is certainly the case in the United Kingdom where the Covid-19 pandemic seems to be under control. The number of new cases has fallen dramatically and has, in turn, been tracked by the decreases in hospitalisations and deaths. As readers of this blog know, although I try to track the global pandemic, I follow events in Canada – particularly Ontario, South Africa, and the UK especially closely.
In my last communique I reported receiving my first AstraZeneca inoculation. This week I am delighted to report that my partner received her second shot. Once again, the location was the food court at the Castle Mall Shopping Centre in the city. The procedure was a model of efficiency, although on a Sunday afternoon, it was quiet. We were in and out in 15 minutes. I asked if they would consider giving me a second dose. I want to be fully protected when I travel in a few weeks. We had an unhurried discussion, and the upshot was that, although they were willing to do the inoculation, we agreed I should wait a couple of weeks. The reason for waiting was that the immunity would be better if there were a longer gap, and, they thought, side effects should be less intense. I cannot praise the NHS and all the voluntary services that are making this happen enough.
The daily UK report on the virus has been of consistent good news. The reported number of new cases, hospitalisations and deaths continue to fall, while the number vaccinated is rising rapidly, including those who have received second doses. This is not the case around the world, the situation in Brazil and India is particularly bleak, not only are the rates going up, but the numbers are extremely high. A quick look at the excess death data gives a sense of bad the epidemic is by country. The New York Times does not seem to have kept their graphs up to date, the Economist has.1 Elsewhere there is cause for cautious optimism, but the price is constant vigilance. The economic, social, and psychological costs remain uncertain. In the UK this uncertainty will continue until the furlough scheme has ended. That will be when we understand how many people have lost their incomes. This will not just be those on furlough but so many small businesses who will either close or may fail.